Prilenia

Prilenia Therapeutics is a clinical-stage biotechnology company focused on developing new treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 by Michael Hayden, a renowned scientist in Huntington's disease research, Prilenia is driven by a mission to slow the progression of these debilitating diseases and provide hope to patients and their families. The company's primary focus is on developing pridopidine, an investigational drug that activates the sigma-1 receptor (S1R), a protein crucial for neuronal function and survival.

Prilenia's research and development efforts are focused on advancing pridopidine as a potential treatment for Huntington's disease (HD) and amyotrophic lateral sclerosis (ALS). The company is also exploring pridopidine's potential in other neurodegenerative diseases and neurodevelopmental disorders. Prilenia has a global presence with offices in the Netherlands, Israel, and the United States, and is backed by a group of well-respected investors.

Prilenia is a global company with offices in the Netherlands, Israel, and the United States, and they are actively looking for individuals who are ready to think creatively, collaborate, and make a difference. Prilenia's employees are mostly remote, working across Israel, Europe, and North America.

Prilenia offers a competitive benefits package that includes health insurance, dental insurance, vision insurance, life insurance, short-term disability insurance, long-term disability insurance, paid time off, paid holidays, and a 401(k) plan. They are a global company with offices in the Netherlands, Israel, and the United States.

Prilenia Therapeutics is a clinical-stage biotechnology company dedicated to developing innovative treatments for patients and families facing Huntington's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative and neurodevelopmental disorders. Their mission is to advance research and create breakthroughs that slow disease progression, preserve quality of life, and ultimately bring hope to those impacted by these challenging conditions.

Prilenia promotes a collaborative, innovative, and passionate work environment. They emphasize the importance of creativity, teamwork, and a strong commitment to making a difference in the lives of patients and their families. With employees working mostly remotely across Israel, Europe, and North America, Prilenia prioritizes clear communication and a dynamic, hands-on approach.

Prilenia Therapeutics is committed to building a diverse, equitable, and inclusive workplace that reflects the global communities they serve. They believe that a diverse workforce fosters innovation, creativity, and a deeper understanding of the needs of patients and families impacted by neurodegenerative and neurodevelopmental disorders. Prilenia values the unique perspectives and experiences of all employees and strives to create a welcoming and supportive environment where everyone feels valued, respected, and empowered to contribute their best work. They are committed to attracting, retaining, and promoting a diverse talent pool through inclusive hiring practices, leadership development programs, and a culture of respect and collaboration.